|
In a new filing with the SEC, Cambridge, MA’s Archemix set terms for its IPO of 4.5 million shares at $12 to $14 per share. The firm, which plans to trade on the NASDAQ Global Market under the symbol “ARCH,” is developing “aptamers,” or short strands of DNA or RNA, as treatments for a variety of ailments.
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.
